18:26 , Nov 9, 2018 |  BC Week In Review  |  Clinical News

Bone stops Phase III of Preob cells in osteonecrosis for futility

Bone Therapeutics S.A. (Euronext:BOTHE) discontinued a Phase III trial of its Preob cells to treat osteonecrosis of the hip after an interim 12-month analysis by a DSMB showed that the trial was unlikely to meet...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
18:50 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Bone's Allob meets in Phase I/IIa for delayed-union bone fractures

In September, Bone Therapeutics S.A. (Euronext:BOTHE) reported interim data from a Phase I/IIa trial in 16 patients with delayed-union fractures of long bones showing that Allob met the primary endpoint of improving radiological Tomographic Union...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Clinical News

Allob: Additional Phase IIa data

Additional data from 8 patients with symptomatic degenerative lumbar disc disease that required interbody fusion in an open-label, Belgian Phase IIa trial showed that a single implantation of Allob mixed with bioceramic granules into the...
07:00 , Oct 11, 2016 |  BC Extra  |  Company News

Management tracks

Musculoskeletal company Bone Therapeutics S.A. (Euronext:BOTHE) said CEO Enrico Bastianelli will depart for personal reasons. CBO Thomas Lienard will be interim CEO. Specialty pharma EffRx Pharmaceuticals S.A. (Lausanne, Switzerland) promoted Lorenzo Bosisio to CEO. He...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Allob: Completed Phase IIa enrollment

Bone Therapeutics completed enrollment of 18 patients in an open-label, Belgian Phase IIa trial evaluating a single implantation of Allob mixed with bioceramic granules. The study enrolled patients with symptomatic degenerative lumbar disc disease that...
07:00 , Apr 18, 2016 |  BC Week In Review  |  Clinical News

Bone-forming cells: Additional Phase IIa data

Additional data from 7 patients ages 40-85 who did not respond to anti-osteoporotic therapy in an investigator-led, open-label, Belgian Phase IIa trial showed that a single infusion of IV Preob led to a >=40% reduction...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Allob: Phase IIa data

Data from the first patient with symptomatic degenerative lumbar disc disease that required interbody fusion in an open-label, Belgian Phase IIa trial showed that a single implantation of Allob mixed with bioceramic granules into the...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Clinical News

Bone-forming cells: Phase IIa data

Data from 7 patients ages 40-85 who did not respond to anti-osteoporotic therapy in the first part of an investigator-led, open-label, Belgian Phase IIa trial showed that a single infusion of IV Preob led to...